EGFR and neoplasm: In contrast, in the TCHL arm, patients with PIK3CA and/or ERBB family mutated tumours were more likely to achieve a pCR than patients with PIK3CA and ERBB WT tumours (77.8% vs. 35%; p = 0.05) (Fig. 3).